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Abstract
Background: The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers.
We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric
trial (NCT03242993) evaluating the 18F-AzaFol (3′-aza-2′-[18F]fluorofolic acid) as the first clinically assessed PET tracer
targeting the FRα.
Material and methods: Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with
measurable lesions (≥ 10mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60
min after the intravenous injection of 327 MBq (range 299–399 MBq) of 18F-AzaFol to establish dosimetry. Organ
absorbed doses (AD), tumor AD, and patient effective doses (E) were assessed using the OLINDA/EXM v.2.0 software
and compared with pre-clinical results.
Results: No serious related adverse events were observed. The highest AD were in the liver, the kidneys, the urinary
bladder, and the spleen (51.9, 45.8, 39.1, and 35.4 μGy/MBq, respectively). Estimated patient and gender-averaged E
were 18.0 ± 2.6 and 19.7 ± 1.4 μSv/MBq, respectively. E in-human exceeded the value of 14.0 μSv/MBq extrapolated
from pre-clinical data. Average tumor AD was 34.8 μGy/MBq (range 13.6–60.5 μGy/MBq).
Conclusions: 18F-Azafol is a PET agent with favorable dosimetric properties and a reasonable radiation dose burden for
patients which merits further evaluation to assess its performance.
Trial registration: ClinicalTrial.gov, NCT03242993, posted on August 8, 2017
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Background
The folate receptor-alpha (FRα) is a transmembrane recep-
tor overexpressed in multiple tumor types and has been
explored as a novel target for cancer treatments [1–3].
However, recent trials evaluating FRα-directed antibodies
or drug conjugates, such as farletuzumab and vintafolide,
did not show any benefit in ovarian cancer patients in phase
III studies [4, 5]. The reasons for these negative results were
certainly multiple but may be partially explained by
heterogenous antigen expression in the cancer tissue and
possible off-target binding.
To better predict the FR-related accumulation of a
possible FRα-ligand, molecular imaging is a valuable op-
tion, which has the advantage to provide a spatial distri-
bution of the disease burden. Pre-treatment imaging is
able to evaluate the target distribution regarding homo-
geneity and if any unforeseen binding (sink effect) might
influence the uptake of the targeted agent [6]. A number
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of FRα-targeting imaging agents have been evaluated to
address this issue. Etarfolatide, a 99mTc complexed folic
acid conjugate has been tested clinically to enable selec-
tion of patients prior to Vintafolide treatment [7, 8].
However, Etarfolatide is a single-photon emission tom-
ography (SPECT) tracer with limited imaging resolution
and inferior quantification compared to positron emis-
sion tomography (PET). In pre-clinical studies, folate-
derived 68Ga-based PET probe has shown slightly super-
ior in vivo performance in comparison to Etarfolide [9].
This compound is to the best of our knowledge under
investigation in humans in an inflammatory indication
(NCT03494114) and currently not published in a peer-
reviewed journal. At the Center for Radiopharmaceutical
Sciences (Villigen-PSI, Switzerland), a series of 18F-based
folate tracers have been developed over the past decade
[10], which resulted recently in a so-called “integrated”
approach where the 18F-label was directly introduced in
the folic acid backbone [11]. Promising pre-clinical re-
sults led to a further optimization and development of
an 18F-based folic acid tracer, 3′-aza-2′-[18F]fluorofolic
acid (herein referred to as 18F-AzaFol), which can be
synthesized in an easy-to-perform one-step labeling ap-
proach suitable for an automated synthesis module [12].
Here, we present the first publication of a human dos-
imetry study of 18F-AzaFol and overall the first clinical




The present study was designed to establish the 18F-Aza-
Fol PET/CT dosimetry as a radiation safety cohort in pa-
tients with adenocarcinoma of the lung. It is part of a
larger, prospective, multi-centric study conducted in
three Swiss hospitals. The study was approved by the re-
spective institutions’ ethics committee, the national
health authorities, centrally monitored by a dedicated,
independent Contract Research Organization and listed
in the trial list of the National Institute of Health Trial
database (NCT03242993).
Patients
Eligible patients had a histologically confirmed non-
small cell lung carcinoma of the lung with measurable le-
sions (≥ 10mm according to RECIST 1.1 [13]) and were
staged by standard of care imaging with an indication for
systemic treatment. The last systemic treatment should
not have been applied within 3 weeks before performing
the study exam. Male and female patients needed to be
18 years or older as well as voluntarily sign the informed
consent form. Exclusion criteria were, in brief, any contra-
indications to the class of drugs under study, pregnancy or
breast-feeding, clinically significant concomitant disease
states (e.g., renal failure, hepatic dysfunction, or cardiovas-
cular disease) and poor performance status (ECOG > 2).
Patients were asked to discontinue taking vitamin supple-
ments containing folic acid 48 h prior to the PET/CT. Due
to pre-clinical results established by our group, all patients
received a single bolus injection of 1mg of folic acid be-
fore tracer administration [12].
Radiochemistry
The precursor (protected 3′-aza-2′-chloro-folate) was
synthesized by an external manufacturer (Merck & Cie,
Schaffhausen, Switzerland). Radiolabeling and subse-
quent global deprotection of the protected 3′-aza-2′-
chloro-folate precursor resulted in 3′-aza-2′-[18F]fluoro-
folic acid herein referred to as 18F-AzaFol. Radiolabeling
of the folate precursor was achieved within 17min at
150 °C in dimethyl sulfoxide (≥ 99.7%, over molecular
sieve, Acros Organics) and the protective groups were
subsequently cleaved under acidic conditions (4M
hydrochloric acid, Merck EMPROVE®) at 60 °C. The
product was purified over two solid-phase extraction
cartridges (30 mg mixed-mode cation exchange sorbent
for bases, particle size 30 μm (MCX), Oasis) and subse-
quently eluted with 50mM phosphate buffer containing
10% methanol (pH 7.4). The desired compound was then
isolated by isocratic HPLC (eluent, 20 mM phosphate
buffer containing 7% methanol pH 7.4; column, Luna
5 μm PFP(2) 100 Å, 250 × 10 mm, Phenomenex; flow
rate, 4 mL/min.; retention time, 11 to 12min). After fur-
ther purification over a third MCX cartridge, formula-
tion was achieved by eluting the product from the MCX
cartridge with 5 mL of 50 mM phosphate buffer contain-
ing 10% ethanol (pH 7.4) into the bulk vial, which was
prefilled with 9mL of saline. The bulk product was then
aseptically dispensed through a sterile filter (Millex-GV,
0.22 μm, PVDF, diameter 33 mm, Millipore) to yield the
final, sterile, and non-pyrogenic product with a total ac-
tivity of approximately 2 GBq in 6 mL plus samples for
quality control, including sterility testing and a retained
sample. Radiochemical purity was ≥ 95% and molar ac-
tivity ≥ 100 GBq/μmol. The analytical HPLC was run
with an isocratic method (column, XSelect HSS PFP XP,
100 Å, 2.5 μm, 4.6 mm × 150mm (Waters); eluent, 10
mM ammonium acetate buffer, pH 6.2 containing 5%
methanol; flow rate, 1 mL/min; UV, 280 nm; radio de-
tector, 2 × 2″ NaI (Tl) crystal). The retention time of
18F-AzaFol was 7.8 min.
PET/CT acquisition protocol
Seven PET images (from the top of the skull to the mid
femora, 1 min/bed position, six bed positions, total scan
length was 6 min) were acquired on a Discovery MI
time-of-flight (TOF) PET/CT (GE Healthcare, Wauke-
sha, WI, USA) at the University Hospital Zurich. All
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pertinent corrections (normalization, dead-time, physical
decay correction at the start of the PET scan, random
coincidence, attenuation, and scatter correction) were
applied. PET field-of-view width was 70 cm with 256 ×
256 image discretization. The voxel size in the axial dir-
ection and transverse plane were, respectively, 2.79 mm
and 2.73 mm. Each patient underwent a low-dose (120
kVp, 15 mA/s, spiral pitch = 0.98, 40 mm beam collima-
tion, CTDIvol = 1.3 mGy) whole-body CT for attenuation
correction prior to the first PET acquisition.
PET data were reconstructed using a proprietary three-
dimensional ordered subset expectation-maximization al-
gorithm (3 iterations × 16 subsets) with TOF information
and PSF recovery correction (VPFXs, vendor-based recon-
struction algorithm) with 6.4-FWHM Gaussian post-
reconstruction filtering.
Patients were instructed to void the urinary bladder
after the 1 h scan period.
Organ segmentation
Co-registered PET and CT data were loaded using PMOD
3.9 (PMOD Technologies, Zurich, Switzerland). Volumes of
interest (VOI) were manually drawn slice-by-slice on the
axial plane of the CT part of each PET/CT study using the
polygonal segmentation tool of PMOD by two operators in
consensus (SG, NS) for the following body regions: brain,
thyroid, lungs, heart, liver, spleen, stomach, kidneys, prostate
(in men), red marrow, intestines, and whole-body. Tumors
with increased folate receptor expression were manually
segmented on CT data using the combined information of
PET/CT and prior standard of care clinical imaging.
The urinary bladder was manually segmented on the
emission PET data to account for possible changes of vol-
ume due to bladder filling between PET/CT acquisitions.
Specific biological uptake was found in the choroid plex-
uses. This small vascular structure was segmented by
emission-based threshold segmentation to avoid import-
ant PET signal spill-out. We adopted a threshold of 5% of
the maximum signal intensity to delineate the choroids
VOI. This relatively low threshold level was possible con-
sidering the negligible tracer uptake of the surrounding
cerebral tissue. An example of source organ VOI segmen-
tation is provided in Supplemental Data 1 (Figure S1).
Absorbed dose (AD) estimations
The total activity contained in each considered source
organ was obtained by multiplying the average activity
concentration (expressed in Bq/mL) by the organ volume
expressed in milliliters and normalized to the adminis-
tered patient activity at each time point. For all source
organs, normalized time-activity curves (nTAC) were
obtained assuming an initial constant uptake (Aorgan (t) =
Aorgan (t = 3min) for 0 min ≤ t < 3min) and thus using a
bi-exponential fit of experimental data extended from t =
3min and the last measured data point (60min post-
administration). Exponential fit parameters were obtained
using the kinetic module of OLINDA/EXM v.2.1. Beyond,
in absence of late measured data, a simple mono-
exponential physical decay was assumed to derive time-
integrated activity coefficients (TIACs) by analytical time
integration of source organ time-activity curves using
MATLAB software (release 2017a; The MathWorks, Inc.,
Natick, MA, USA).
Bone marrow dosimetry was estimated by combining
information from different VOIs as previously reported
[14]. In brief, the red marrow time-integrated activity co-
efficient (TIAC) was obtained from nTAC in which the
red marrow activity concentration (Bq/mL) was sampled
in VOIs drawn in the humeral bone, the heads of fem-
ora, and lumbar vertebrae (L3–L4). The total activity in
the red bone marrow was obtained by multiplying the
average activity concentration measured in the sampled
VOIs by the total red marrow mass of ICRP-89 adult
male/female reference phantoms [15], which was re-
peated for each patient and at each acquired time point.
To estimate the colon AD, the total number of colonic
disintegrations was partitioned to its components (right
colon, left colon, and rectum) proportionally to their re-
spective masses of the ICRP-89 male and female refer-
ence phantoms [15].
The total amount of radioactivity excreted from the
body through the urine was not quantitatively assessed
as no urine samples were collected in this study. We es-
timated the total amount of radioactivity present in the
urinary bladder at 1 h after administration (latest quanti-
tative PET acquisition available). This amount of radio-
activity was assumed to be completely voided just after
the last PET acquisition, when the patient was allowed
voiding at the toilet. To obtain the TIAC for the urinary
bladder, the excreted fraction (the voided activity at 1 h di-
vided by the patient-administered activity) was used in in-
put to the special kinetic module of OLINDA/EXM 2.1
for the urinary bladder voiding using a voiding period of
1 h. We adopted this methodology in the absence of urine
samples and PET acquisition for t > 60min.
The TIAC for the rest of the body was obtained by
subtracting the sum of the source organ TIACs from the
whole-body TIAC.
TIACs were used in input to the OLINDA/EXM® 2.0
code (HERMES Medical Solution AB, Stockholm,
Sweden) [15] that provided organ AD and effective dose
(E) per unit of administered activity in μGy/MBq and μSv/
MBq, respectively, using the NURBS voxel-based phan-
toms [16] adjusted to the ICRP-89 organ masses [17] and
ICRP103 tissue weighting factors (wT) [18]. According to
publication ICRP 103, E is calculated as the weighted aver-
age of organ/tissue equivalent doses, summing equivalent
doses multiplied by tissue weighting factors (wT), which
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provide a simplified representation of fractional contribu-
tions to total stochastic detriment from cancer and herit-
able effects. While exposures may relate to individuals or
population groups, E is calculated for reference persons.
For a general population, ICRP recommends to average E
computed for a reference male and a reference female
phantom. We will call this quantity “gender-averaged E.” In
this paper, we will also compute E for specific patients,
which we will refer as “patient E” using the reference organ
masses of OLINDA/EXM 2.0, thus adopting a methodo-
logical approach typical of radiation protection, where the
dosimetry of a reference adult subject is the focus.
A specific dose assessment was performed for the choroid
plexuses and tumors, which do not appear in the list of
available source/target organs in OLINDA. Trapezoidal
time integration of the normalized time-activity curve, for 0
≤ t ≤ 60min, was performed using MATLAB software (re-
lease 2017a; The MathWorks, Inc., Natick, MA, USA), ana-
lytical integration assuming mono-exponential physical
decay was applied beyond. To account for loss of signal due
to partial volume effects (PVE), tumor TIACs were cor-
rected using recovery coefficients (RC) obtained in a
NEMA/IEC NU2 phantom experiment using the same clin-
ical acquisition and reconstruction parameters used for the
patient study as reported in Supplemental material (Supple-
mental Data 2). TIACs for the choroid and tumors were
used as input in the OLINDA sphere model. For the cho-
roids, we also applied a more realistic AD estimation using
the Monte Carlo-derived analytical approach proposed by
Amato et al. [19] in which the complex geometry of this
organ was approximated using a set of simple geometrical
structures such as (cylinders and parallelepipeds). The mass
of the choroids was estimated to be 2.76 g and 1.81 g for
male and female as previously reported in [20].
We performed an additional analysis to investigate the in-
fluence of the nTAC extrapolation to infinity on source organ
TIACs. At this scope, in addition to the assumption of pure
physical decay from t > 60min, we also computed mean
source organ TIACs (obtained from the time integration of
averaged nTACs across the six patients) by assuming mono-
and bi-exponential prolongation to infinity of the nTACs.
Coefficients of determination (R2) were computed to
evaluate the goodness of both mono-exponential and bi-
exponential nTAC fits for source organs exhibiting a
monotonic decreasing uptake or decreasing activity
accumulation with time (all considered source organs
except the urinary bladder).
Tumor contrast
We characterized the tumor to background contrast as a
function of the time elapsed after radiotracer administra-
tion; with this aim, we computed for each acquired PET
the tumor to lung ratio (T/L) by dividing the average activ-
ity concentration measured in lung tumor VOIs by the
average activity concentration measured in the lung VOI.




Six patients with non-small cell lung cancer were in-
cluded in this dosimetric study (2 women, 4 men; aver-
age age 72 ± 10 years, average body mass 73 ± 15 kg and
average height 1.67 ± 0.07 m). Participant demography
and injection data are reported in Supplemental Data 3.
Each patient underwent 7 consecutive whole-body TOF
PET/CT acquisitions at 3 ± 1, 11 ± 1, 18 ± 1, 30 ± 3, 40
± 3, 50 ± 1, and 60 ± 3min after the intravenous admin-
istration of 327 ± 37MBq (range 299–399MBq) of 18F-
AzaFol. All injections were well tolerated. No immediate
symptoms or modification of vital signs were observed.
Imaging
A typical biodistribution of 18F-AzaFol is shown in Fig. 1
(MIP images at 60 min for the six patents are shown in
Figure S4 of Supplemental Data 4). The main way of
biological excretion of the radiopharmaceutical from the
body was through the urine. Prominent kidney uptake
was visible in the early phase followed by rapid renal
wash-out. Significant urinary bladder activity accumula-
tion was seen as early as 10 min after injection. A signifi-
cant uptake was observed in the choroid plexuses from
the early time point images (Fig. 2).
Absorbed dose estimations of 18F-AzaFol in humans
Bio-kinetic data (percent of injected activity normalized by
the source organ mass at different measured time points),
for relevant source organs, the choroid plexuses and the
tumors, corrected for 18F physical decay are shown in Fig.
3. nTAC data for the six patients considered in this study
were reported as supplemental material (Supplemental
Data 5). Figure 4 shows, for each considered source organ,
mean normalize activity (nA) ± SD (average values and
SD evaluated across all six patients), mono-, and bi-
exponential fits, in addition to the tail representing pure
physical decay to infinity for t > 60min. Table 1 reported
the R2 values of mono- and bi-exponential nTAC fits. In
most source organs, higher R2 values were obtained
adopting a bi-exponential fit of experimental data.
Computed source organ TIACs are reported in Table
2. Organ AD, patient E, as well as the extrapolated E for
the reference person, are reported in Table 3. The organ
receiving the highest AD (mean ± SD) was the liver
(51.9 ± 16.4 μGy/MBq), followed by the kidneys, the
urinary bladder wall, and the spleen (45.8 ± 8.3, 39.1 ±
16.8 and 35.4 ± 39.7 μGy/MBq respectively). Using a 1-h
urinary voiding cycle, we obtained an averaged E of 18.0
± 2.6 μSv/MBq in our patient cohort. The corresponding
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E for the reference person was 19.7 ± 1.4 μSv/MBq. AD
in tumor was 34.8 ± 17 μGy/MBq (range 13.6-60.5 μGy/
MBq). The estimated AD in the choroid plexuses, for
the two dosimetry approaches used (OLINDA spherical
model and Monte Carlo-derived analytical calculation),
are reported in Table 4.
Tumor uptake and contrast
We analyzed nine lung tumors across the six patient popu-
lation. The average tumor uptake in terms of percentage-
injected activity per gram (%IA/g) corrected for 18F physical
decay is indicated in Fig. 3. Averaged %IA/g monotonically
increased over time, nearly reaching a plateau within the
60min after radiopharmaceutical administration. Individual
tumor TACs and %IA/g are shown in supplemental mater-
ial Figure S6 (Supplemental Data 6).
We measured the T/L on nine lung tumors. As shown
in Table 5, the average T/L varied between 3.5 at the
time of the first PET acquisition and remains between
4.8 and 5 for PET acquisition time ≥ 40min where the
Fig. 1 Example of maximum intensity projections 3, 11, 18, 30, 40, and 60min post-tracer administration (p.a) showing in-patient 18F-Azafol
activity distribution
Fig. 2 Typical 18F-AzaFol uptake pattern in the choroid plexuses (lateral ventricles) for a representative patient at 30 min post-administration
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Fig. 3 Biological organ kinetic of 18F-AzaFol corrected for 18F physical decay. Color bars represent the average percent of injected activity per
gram of tissue (%IA/g) ± 1SD, for each time point
Fig. 4 Mean nA ± SD (average values and SD evaluated across the 6 patients), for considered source organs. Mono- and bi-exponential fits of
experimental data are displayed in addition to the tail according to pure physical decay to infinity for t > 60min. For sake of visibility, the time
base in each source organ graph was restricted to three times the physical half-life of 18F
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T/L reach a plateau. Based on these results, we estimate
an optimal acquisition PET time between 40min and 1 h
post-administration.
Discussion
To the best of our knowledge, this is the first clinical
study publication describing a FR-targeting PET agent.
Our data show the liver to be the most irradiated
organ in 18F-AzaFol PET imaging, followed by the kid-
neys, the urinary bladder wall, and the spleen, with a
mean E of 18.0 ± 2.6 μSv/MBq corresponding to an ef-
fective dose of 5.9 ± 0.8 mSv (range 5.4–7.2 mSv). The
reference person E was 19.7 ± 1.4 μSv/MBq, which is
comparable to the radiation burden of 19.0 μSv/MBq for
18F-FDG PET imaging [21, 22].
Measured PET data were obtained during the first
hour after radiopharmaceutical administration and the
source organ TIACs were obtained by performing ana-
lytical time integration of nTAC bi-exponential fits for 3
min ≤ t ≤ 60 min. In this time interval, in fact, the bi-
exponential fits were characterized by a (slightly) higher
R
2 compared to the mono-exponential fits. In the ab-
sence of information for 0 ≤ t < 3min, we decided to as-
sume a constant organ uptake with a pure mono-
exponential physical decay (with the characteristic 18F
half-life of 110min) for t > 60min. This approach has
been adopted when lacking later PET acquisitions and
potentially leads to conservative (over-) estimates of the
actual organ AD and E. As reported in Fig. 4, for some
source organs, the bi-exponential fits exhibited a late
Table 1 Goodness of fit expressed by the coefficient of
determination R2 for considered source organs average nA
values fitted with mono- and bi-exponential functions (averaged
nA and fits are visible in Fig. 1). The average nA were computed
from experimental data collected across the six-patient dataset




Heart contents 1.000 0.861
Liver 0.856 0.856
Stomach contents 1.000 1.000
Spleen 0.997 0.982
Kidneys 1.000 0.949
Small intestine 0.999 0.946
Left colon 0.996 0.945
Right colon 0.996 0.943
Rectum 0.999 0.945
Prostate (in men) 0.968 0.961
Red marrow 0.662 0.662
Rest of the body 0.999 0.999
Whole body 1.000 1.000
Table 2 Time-integrated activity coefficients (TIAC in units of MBq h/MBq) for source organs considered in the dosimetry study. Two
male patients had surgical prostate resection before inclusion in this study
Source organ/patient (gender) 1 (F) 2 (M) 3 (F) 4 (M) 5 (M) 6 (M) Average SD
Brain 1.30E− 02 6.60E− 03 1.15E− 02 7.20E− 03 6.30E− 03 6.60E− 03 8.53E− 03 2.93E− 03
Thyroid 3.00E− 04 8.00E− 04 4.00E− 04 8.00E− 04 2.50E− 03 5.00E− 04 8.83E− 04 8.18E− 04
Lungs 1.11E− 01 1.09E− 01 7.88E− 02 1.58E− 01 1.13E− 01 7.04E− 02 1.07E− 01 3.08E− 02
Heart 2.02E− 02 2.31E− 02 2.33E− 02 1.60E− 02 1.45E− 02 1.89E− 02 1.93E− 02 3.61E− 03
Liver 4.73E− 01 2.72E− 01 2.63E− 01 2.98E− 01 2.58E− 01 3.70E− 01 3.22E− 01 8.48E− 02
Stomach 3.54E− 02 7.70E− 03 1.82E− 02 2.19E− 02 8.50E− 03 1.78E− 02 1.83E− 02 1.01E− 02
Spleen 1.09E− 02 6.60E− 03 8.60E− 03 6.50E− 03 7.80E− 03 9.09E− 02 2.19E− 02 3.38E− 02
Kidneys 5.02E− 02 5.10E− 02 7.68E− 02 4.97E− 02 6.96E− 02 5.37E− 02 5.85E− 02 1.17E− 02
Small Intestine 6.66E− 02 4.96E− 02 3.00E− 02 5.38E− 02 4.94E− 02 7.89E− 02 5.47E− 02 1.67E− 02
Left colon 1.42E− 02 1.06E− 02 6.50E− 03 1.15E− 02 1.06E− 02 1.69E− 02 1.17E− 02 3.54E− 03
Right colon 2.85E− 02 2.12E− 02 1.29E− 02 2.31E− 02 2.12E− 02 3.38E− 02 2.35E− 02 7.13E− 03
Rectum 1.42E− 02 1.06E− 02 6.50E− 03 1.15E− 02 1.06E− 02 1.69E− 02 1.17E− 02 3.54E− 03
Prostate (in men) – 2.20E− 03 – – 1.10E− 03 – 1.65E− 03 7.78E− 04
Red marrow 1.31E− 02 2.42E− 02 3.38E− 02 2.03E− 02 1.33E− 01 2.86E− 02 4.22E− 02 4.50E− 02
Urinary bladder 8.12E− 02 5.49E− 02 8.82E− 02 4.76E− 02 5.08E− 02 5.74E− 03 5.47E− 02 2.93E− 02
Rest of the body 1.46E+ 00 1.82E+ 00 1.72E+ 00 1.77E+ 00 1.71E+ 00 1.81E+ 00 1.71E+ 00 1.33E− 01
M male, F female
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Table 3 Average organ AD and E according to OLINDA/EXM 2.0 for a 1-h urinary voiding cycle. Reference organ masses for the
adult male (M) and adult female (F) Reference phantoms of OLINDA/EXM 2.0 were used
Organ AD in mGy/MBq
Organs/patient 1 (F) 2 (M) 3 (F) 4 (M) 5 (M) 6 (M) Average SD
Adrenals 2.61E− 02 1.93E− 02 2.27E− 02 2.00E− 02 2.06E− 02 2.52E− 02 2.23E− 02 2.84E− 03
Brain 4.67E− 03 3.26E− 03 4.80E− 03 3.32E− 03 3.36E− 03 3.27E− 03 3.78E− 03 7.42E− 04
Breasts 9.68E− 03 – 1.01E− 02 – – – 9.89E− 03 2.97E− 04
Esophagus 1.63E− 02 1.29E− 02 1.45E− 02 1.37E− 02 1.25E− 02 1.37E− 02 1.39E− 02 1.35E− 03
Eyes 7.77E− 03 7.76E− 03 9.04E− 03 7.58E− 03 7.57E− 03 7.73E− 03 7.91E− 03 5.61E− 04
Gallbladder wall 2.33E− 02 2.05E− 02 1.97E− 02 2.15E− 02 2.00E− 02 2.47E− 02 2.16E− 02 1.99E− 03
Left colon 2.89E− 02 2.45E− 02 2.15E− 02 2.56E− 02 2.46E− 02 3.32E− 02 2.64E− 02 4.10E− 03
Small intestine 3.44E− 02 2.54E− 02 2.32E− 02 2.64E− 02 2.53E− 02 3.37E− 02 2.81E− 02 4.76E− 03
Stomach wall 3.05E− 02 1.57E− 02 2.23E− 02 2.19E− 02 1.57E− 02 2.22E− 02 2.14E− 02 5.47E− 03
Right colon 3.09E− 02 2.62E− 02 2.19E− 02 2.74E− 02 2.60E− 02 3.50E− 02 2.79E− 02 4.52E− 03
Rectum 3.05E− 02 2.42E− 02 2.39E− 02 2.48E− 02 2.41E− 02 3.06E− 02 2.64E− 02 3.27E− 03
Heart wall 2.04E− 02 1.78E− 02 2.06E− 02 1.72E− 02 1.57E− 02 1.78E− 02 1.83E− 02 1.91E− 03
Kidneys 4.54E− 02 3.85E− 02 6.01E− 02 3.80E− 02 4.96E− 02 4.31E− 02 4.58E− 02 8.25E− 03
Liver 8.34E− 02 4.08E− 02 4.95E− 02 4.45E− 02 3.92E− 02 5.38E− 02 5.19E− 02 1.64E− 02
Lungs 2.84E− 02 2.19E− 02 2.19E− 02 2.89E− 02 2.25E− 02 1.77E− 02 2.36E− 02 4.31E− 03
Ovaries 1.46E− 02 – 1.56E− 02 – – – 1.51E− 02 7.07E− 04
Pancreas 2.30E− 02 1.55E− 02 1.94E− 02 1.65E− 02 1.53E− 02 1.87E− 02 1.81E− 02 2.94E− 03
Prostate – 2.98E− 02 – 1.30E− 02 1.93E− 02 1.95E− 02 2.04E− 02 6.96E− 03
Salivary glands 8.62E− 03 9.16E− 03 9.91E− 03 8.99E− 03 8.88E− 03 9.13E− 03 9.12E− 03 4.36E− 04
Red marrow 1.26E− 02 1.17E− 02 1.47E− 02 1.15E− 02 1.89E− 02 1.23E− 02 1.36E− 02 2.83E− 03
Osteogenic cells 9.65E− 03 9.61E− 03 1.11E− 02 9.44E− 03 1.36E− 02 1.01E− 02 1.06E− 02 1.60E− 03
Spleen 2.56E− 02 1.55E− 02 2.22E− 02 1.58E− 02 1.73E− 02 1.16E− 01 3.54E− 02 3.97E− 02
Testes – 9.50E− 03 – 9.20E− 03 9.04E− 03 9.14E− 03 9.22E− 03 1.98E− 04
Thymus 1.35E− 02 1.16E− 02 1.36E− 02 1.19E− 02 1.11E− 02 1.14E− 02 1.22E− 02 1.09E− 03
Thyroid 9.26E− 03 1.28E− 02 1.02E− 02 1.32E− 02 2.56E− 02 1.03E− 02 1.36E− 02 6.10E− 03
Urinary bladder wall 5.54E− 02 3.72E− 02 6.00E− 02 3.34E− 02 3.48E− 02 1.36E− 02 3.91E− 02 1.68E− 02
Uterus 1.77E− 02 – 1.83E− 02 – – – 1.80E− 02 4.24E− 04
Total body 1.39E− 02 1.11E− 02 1.37E− 02 1.11E− 02 1.11E− 02 1.16E− 02 1.21E− 02 1.35E− 03
Patient E (wT ICRP-103) mSv/MBq 2.28E− 02 1.53E− 02 1.91E− 02 1.70E− 02 1.67E− 02 1.73E− 02 1.80E− 02 2.62E− 03
Reference person E
(wT ICRP-103) mSv/MBq
2.16E− 02 1.82E− 02 1.80E− 02 2.01E− 02 1.98E− 02 2.05E− 02 1.97E− 02 1.38E− 03
Table 4 Dosimetry assessment in choroid plexuses. The average TIAC value was used in input to the OLINDA/EXM sphere model
and to the Monte Carlo-derived analytical model [17]
Choroid plexuses TIAC (MBq h/MBq)
Average Min Max SD
4.62E− 04 3.72E− 04 5.15E− 04 5.81E− 05
Choroid plexuses AD (μGy/MBq)
OLINDA sphere model, M (2.76 g) OLINDA sphere model, F (1.81 g) M-C Analytic, M (2.76 g) M-C Analytic, F (1.81 g)
2.47E− 02 3.69E− 02 2.25E− 02 3.22E− 02
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effective half-life higher than the 18F physical half-life,
thus resulting in unrealistic TIAC (and AD) extrapola-
tions when the time integration was extended to infinity.
Another possible option would be consisted in adopting
a mono-exponential extension to infinity of source organ
nTACs. This approach would result in an average of
20% lower TIACs, but, because of the lack of experimen-
tal data for t > 60 min, we preferred to keep a conserva-
tive approach by adopting the physical decay to infinity.
Tumors and choroidal plexuses showed an initially
growing uptake followed by a late decrease; this fact mo-
tivated our adoption of a trapezoidal numerical integra-
tion for t ≤ 60 min.
We derived RCs from a NEMA/IEC phantom experi-
ment (provided in Supplemental Data 2) and used them to
correct tumor TIACs to compensate for PVE. Among con-
sidered source organs, only the thyroid had a size (male
thyroid ICRP-89 volume = 20, mL, RC (20mL) = 0.77) that
would motivate the use of PVE compensation. This com-
pensation was not applied. Nevertheless, the thyroid exhib-
ited very little (and unspecific) radiotracer uptake with
consequent minor impact on E determination (3% of E).
In a phase-I study using 99mTc-Etarfolatide, (22)
Yamada et al [23], reported an E of 8.9 μSv/MBq, trans-
lating into an E of 6.6 mSv for a standard administration
of 740MBq. This E is therefore comparable to the E we
reported for our PET tracer.
We computed doses according to OLINDA/EXM 2.0
reference-phantom organ masses. This approach is ap-
plied in the low-dose range typical of radiopharmaceuti-
cals used for diagnostic purposes in which the patient’s
radiation protection is the main concern, considering
the fact that E is a metric used for assessing stochastic
risks in a population.
It is known that folic acid plays a prominent role in the
development, function, and repair of the central nervous
system [24]. Choroid plexuses, a vascular structure local-
ized in the brain ventricles and responsible for producing
the cerebrospinal fluid, is involved in maintaining the fol-
ate concentration gradient in that fluid. Specific folate up-
take by choroidal plexuses epithelial cells was already
reported in rat’s models [25, 26] and folate receptors in tu-
mors of the choroid plexus were proposed as potential tar-
gets for radiation therapy in mice [27]. 18F-AzaFol showed
a specific biological uptake in choroid plexuses. Notably,
choroid plexuses appear to still be in the biological uptake
phase at the end of the acquisition time (Fig. 3). Estimated
TIAC for the choroid plexuses with 18F-AzaFol (4.62E−
04MBq h/MBq) is higher than TIAC previously reported
in [20] where a 68Ga-RGD compound was used (3.08E−
04MBq h/MBq). Nevertheless, when considering the
same organ mass and geometry (with OLINDA sphere
model and a mass of 2.76 g) used for the AD calculation,
the AD estimate to the choroid plexuses for the 18F-Aza-
Fol (2.47E− 02 μGy/MBq) was lower than the dose esti-
mated of the 68Ga-RGD compound (3.96E− 02 μGy/MBq).
This fact can be explained by the lower average energy of
the β+-emission of 18F compared to 68Ga (0.25 vs. 0.83
MeV). Although there are no specific dose constraints for
the choroid plexuses in external beam radiotherapy for in-
stance, in our opinion, the relatively high doses delivered
to these structures warrants further consideration, espe-
cially in case of any therapeutic applications of folate-
based radioconjugates.
In our dose extrapolation from previously published pre-
clinical data [12], the kidneys followed by the liver were the
organs with the highest exposure. This is the opposite of
what was obtained in the direct human dosimetry. Al-
though, as reported elsewhere [28], the order of the most
irradiated organs can differ between human-measured dos-
imetry and its extrapolation from murine bio-kinetic data.
The E extrapolated from pre-clinical data was predicted
to be 14.0 μSv/MBq, which did underestimate the measured
human E of 19.7 μSv/MBq by 29%. Such large discrepancies
are not uncommon [29, 30]. The underestimation could be
explained by a generally slower metabolism and elimination
of the radiation carrier substance in humans compared to
mice [31]. In addition, available mice bio-kinetic data
missed of dosimetric information for some source organ,
such as the urinary bladder, which also contributed signifi-
cantly to the overall E. Also, note that the mice data used
to extrapolate the human absorbed dose were collected at
only three time points that differed from the human data
points (30, 60 and 90min vs. 3, 11, 18, 30, 40, 50 and 60
after injection respectively). These methodological differ-
ences could partly contribute to the aforementioned
absorbed dose differences, a reality which highlights the im-
portance of performing dedicated in-human dosimetry
studies to complement pre-clinical results prior to any clin-
ical use of radiopharmaceuticals.
Table 5 T/L measured for nine lung tumors as a function of the
time elapsed after radiopharmaceutical administration. In
bracket, we indicated the patient identifier
Time (min post-admin) 3 11 18 30 40 50 60
T1 (P1) 2.22 2.32 2.42 2.37 2.49 2.35 2.39
T2 (P3) 2.58 3.04 3.43 3.03 3.71 3.65 3.39
T3 (P3) 2.67 3.88 4.44 4.14 4.86 5.06 4.65
T4 (P4) 4.60 5.72 5.89 6.19 6.75 6.62 6.59
T5 (P4) 4.90 6.04 6.23 6.65 7.21 7.08 7.08
T6 (P5) 1.74 2.42 2.67 2.93 2.75 2.77 2.71
T7 (P5) 5.79 8.41 9.27 9.21 8.90 8.90 8.87
T8 (P5) 1.78 2.00 2.09 2.06 2.14 2.07 2.00
T9 (P6) 5.32 5.06 4.89 5.22 5.17 5.89 5.65
Average 3.51 4.32 4.59 4.65 4.89 4.93 4.81
SD 1.62 2.15 2.30 2.38 2.35 2.38 2.39
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Recent developments in the field of FRα-based ther-
apies such as chimeric antigen receptor T (CAR-T)
cell therapy in acute myeloid leukemia [32], triple-
negative breast cancer [33], gastric cancer [34], or
ovarian cancer [35] are very promising. Pre-clinical
and clinical results suggest that besides careful clinical
patient selection, such therapies might benefit from
the application of the best possible FRα-based im-
aging agent to improve further patient selection [10].
18F-AzaFol is a ready-to-use diagnostic radiopharma-
ceutical, which could be integrated into many ongoing
clinical programs with antibody-drug conjugates (e.g.,
mirvetuximab-soravtansine) or CAR-T cells. Overall,
we believe our novel PET tracer 18F-AzaFol to be
very promising regarding a clinical application, where
it might serve as a companion diagnostic tool for
FRα-targeting anticancer drugs. Furthermore, our data
were obtained in a multicentric, prospective study
underlining the feasibility of larger trials.
However, it has to be critically acknowledged that
this dosimetric study has several limitations. First, it
has a small number of patients, which is however
comparable to other dosimetric studies and it is part
of a larger prospective trial being currently analyzed.
Secondly, we could not acquire data after 60 min be-
cause of total dose constraints imposed by the regu-
lating authorities. As discussed above, this most likely
leads to overestimated doses due to our conservative
approach of extrapolating the physical decay to infin-
ity. Furthermore, our untreated patient population
was symptomatic by pain and shortness of breath and
imaging > 60 min was very challenging and ethically
questionable. Third, our trial was open for lung
adenocarcinoma and ovarian cancer. This is due to a
known overexpression of these tumors in previously
published histology studies [36]. There are also re-
ported overexpression in other malignancies which
were not addressed in our trial due to a most
possible sound trial design and homogeneity of the
patient population. In this initial dosimetry study, we
only included lung cancer patients despite this trial
was open for lung cancer and ovarian cancer. This is
because of the need of urgent chemotherapy initiation
in patients with recurrent ovarian cancer.
Conclusions
In conclusion, our study showed that 18F-AzaFol is a
safe PET agent with good dosimetric properties with a
reasonable radiation dose burden for patients. Consider-
ing the large number of ongoing clinical trials evaluating
FRα-targeted cancer drugs, this imaging tracer merits
further investigation of its clinical potential as a predict-
ive biomarker.
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